Senhwa submitted multiple IND application to US FDA and Health Canada for the treatment of solid tumours

▴ Senhwa submitted multiple IND application to US FDA and Health Canada for the treatment of solid tumours
Senhwa announces multiple IND application submissions to US FDA and Health Canada evaluating its investigational drug, CX-5461, for the treatment of patients with solid tumours with BRCA2 or PALB2 mutations

Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, recently announced that it has submitted multiple Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA) and Health Canada evaluating its investigational drug, CX-5461, for the treatment of patients with solid tumours with BRCA2 or PALB2 mutations.

"This IND submission is a key milestone in the clinical development of CX-5461. In a phase I study conducted by Senhwa's clinical partner, Canadian Cancer Trial Group (CCTG), CX-5461 demonstrated clinically meaningful and lasting benefits in patients with specific tumor biomarkers that were resistant to platinum and other chemotherapeutics. The US and Canada clinical trials are being designed to further confirm the efficacy seen," said Dr John Soong, Chief Medical Officer of Senhwa Biosciences.

CX-5461 was recently named as a PCF-Pfizer Global Challenge Award recipient. Specifically, it will be used in combination with Pfizer's PARP inhibitor (PARPi), Talazoparib, to explore the therapeutic potential in prostate cancer, which is the second-leading cause of cancer death for men in the United States. In 2016, a recipient of the Stand Up to Cancer's Dream Team Grant selected CX-5461 to study in their Phase I trial. This study's clinical findings were featured in a spotlighted presentation at the 2019 annual San Antonio Breast Cancer Symposium. Due to the DNA repair defect, BRCA1/2 deficient tumour cells are more sensitive to PARPi through the mechanism of synthetic lethality. However, PARPi resistance is ubiquitous in clinic. More than 40% of BRCA1/2-deficient patients fail to respond to PARPi.

"CX-5461 is a first-in-class G-quadruplex stabilizer within a novel class of therapy that accelerates dsDNA breaks and has proven human efficacy across certain tumour types. We believe CX-5461 has great potential as a therapeutic for patients who have developed resistance to PAPRi or other chemotherapies. This continues to be an unmet medical need in cancer treatment," said Dr Tai-Sen Soong, CEO of Senhwa Biosciences.

CX-5461 is designed to stabilize DNA G-quadruplexes of cancer cells and leads to disruption of the cell's replication fork. While acting in concert with Homologous Recombination (HR) pathway deficiency, such as BRCA1/2 mutations, replication forks stall and cause DNA breaks, resulting in cancer cell death. CX-5461 in combination with Homologous Recombination Deficiency (HRD) tumours may be exploited through a synthetic lethality approach, targeting DNA repair defects in HRD tumours.

Tags : #SenhwaBiosciences #LatestNewsonSenhwaBiosciences26thNov #LatestPharmaNews26thNov #LatestNewsonCancerTreatment26thNov #HealthCanada #USFDA #CanadianCancerTrialGroup #PCF-PfizerGlobalChallengeAward #LatestNewsonProstateCancer26thNov #UnitedStates

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

The Surprising Link Between Sleep and Age Perception: What You Need to KnowMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 StudyMarch 29, 2024
Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024
Surmandal's Tribute to the Legends of Hindustani Classical MusicMarch 26, 2024
In Moscow, over 350,000 mammograms have been analyzed using artificial intelligence as part of the compulsory health insurance programMarch 26, 2024